[1] U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis, Retrieved January 14, 2022, from https://www.businesswire.com/news/home/20220114005394/en
[2] Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema, Retrieved January 14, 2022, from https://www.fiercepharma.com/pharma/pfizer-s-next-blockbuster-cibinqo-snags-fda-approval-to-challenge-sanofi-and-regeneron-s